Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of dementia
3.2.1.2 Growing emphasis on early diagnosis and intervention
3.2.1.3 Technological advancements in diagnosis and treatment methods
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of drug development
3.2.2.2 High failure rate in clinical trials
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Cholinesterase inhibitors
5.3 NMDA receptor antagonist
5.4 Combination drugs
5.5 Glutamate inhibitors
5.6 MAO inhibitors
5.7 Other drug classes
Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Alzheimer’s disease
6.3 Parkinson disease dementia
6.4 Vascular dementia
6.5 Lewy body dementia
6.6 Frontotemporal dementia (FTD)
6.7 Other indications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Injectable
7.4 Transdermal patch
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Biogen
10.3 Cipla Inc.
10.4 Daiichi Sankyo Company, Limited
10.5 Eisai Co., Ltd.
10.6 Eli Lilly and Company
10.7 Merck & Co., Inc.
10.8 Novartis AG
10.9 Otsuka Pharmaceutical Co., Ltd.
10.10 Sun Pharmaceutical Industries Ltd.
